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The Inflammasomes in Autoinflammatory Diseases with Skin
Involvement
Hans-Dietmar Beer1,2, Emmanuel Contassot1,2 and Lars E. French1
During the past years, significant progress in the understanding of the complexity, regulation, and relevance of
innate immune responses underlying several inflammatory conditions with neutrophilic skin involvement has
been made. These diseases belong to the novel class of autoinflammatory diseases, and several are caused by
mutations in genes regulating the function of innate immune complexes, termed inflammasomes, leading to
enhanced secretion of the proinflammatory cytokine IL-1b. Consequently, targeting of IL-1b has proven successful
in the treatment of these diseases, and the identification of related pathogenic mechanisms in other more
common skin diseases characterized by autoinflammation and neutrophilic tissue damage also provides
extended opportunities for therapy by interfering with IL-1 signaling.
Journal of Investigative Dermatology (2014) 134, 1805–1810; doi:10.1038/jid.2014.76; published online 6 March 2014
INTRODUCTION
Our skin, and particularly its outermost
part, the epidermis, is regularly exposed
to numerous physical, chemical, and
biological insults. Integrity and home-
ostasis are maintained thanks to appro-
priate defense mechanisms that include
the epidermal barrier and adequate
innate immune responses. The latter can
be triggered by a large variety of insults in
a very rapid but relatively unspecific
manner through the recognition of con-
served exogenous and endogenous mole-
cules that are sensed by a number of
mechanisms, including multimolecular
intracellular protein complexes called
inflammasomes. The first report of an
inflammasome as a molecular platform
triggering inflammation was made
in August 2002 (Martinon et al., 2002).
Since then, a large body of basic and
translational research has shown that the
inflammasome is an important com-
ponent of the innate immune response
critically involved in inflammation.
INFLAMMASOMES
Toll-like receptors are able to induce
an inflammatory response. They do so
through the induction of inflammatory
gene expression upon sensing of patho-
gen-associated molecular patterns that
are conserved molecules from microbes
(Beutler, 2009). In contrast, inflamma-
somes mount an inflammatory response
by different mechanisms and pathways
(see below) (Strowig et al., 2012).
Interestingly, they assemble not only
upon sensing of pathogen-associated
molecular patterns but also when cells,
usually macrophages or dendritic cells,
come into contact with endogenous
molecules released by damaged or
injured cells, thus termed danger- or
damage-associated molecular patterns
(DAMPs). Activation of Toll-like
receptors is in part a prerequisite for
inflammasome activation or for their
downstream pathways, as this priming
induces expression of certain inflam-
masome proteins (e.g., NLRP3 (NOD,
leucine-rich repeat and pyrin domain
containing protein 3)) or of their down-
stream target proIL-1b (Burns et al.,
2003; Bauernfeind et al., 2009). All
inflammasomes consist of a central
scaffold and sensor protein (a Nod-like
receptor: NLRP1, NLRP3, NLRC4, and
NLRP6 or an HIN (hematopoietic IFN-
inducible nuclear antigen) domain
protein: AIM2 (absent in melanoma 2)
or IFI16 (IFN-g-inducible protein 16)),
the adaptor protein ASC (apoptosis-
associated speck-like protein contain-
ing a CARD), and the effector protein
caspase-1. In addition to this core com-
position, other proteins including NAIPs
(NLR family, apoptosis inhibitory
proteins), PKR (double-stranded RNA-
dependent protein kinase), or caspase-4
have been identified that are necessary
for the activation of one or several types
of inflammasomes (Kofoed and Vance,
2011; Lu et al., 2012; Sollberger et al.,
2012). It seems that in most cases, indi-
vidual pathogen-associated molecular
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patterns and DAMPs activate specific
inflammasomes and that pathogens
and stress factors, which cause inflam-
mation due to more than a single type of
inflammasome, represent exceptions
(Wu et al., 2010). AIM2 and IFI16
assemble with ASC and caspase-1
upon direct binding of double-stranded
cytoplasmic or nuclear DNA, respec-
tively (Strowig et al., 2012). However,
the molecular mechanisms resulting
in activation of the other types of
inflammasomes are less clear.
INFLAMMASOME EFFECTOR
MECHANISMS
Upon inflammasome assembly, the pro-
tease caspase-1 is activated and the
cleavage of its known (and unknown)
substrates differentially contributes to
inflammation. Clearly, biologically inac-
tive proIL-1b is its most important sub-
strate (Dinarello, 2009). This is reflected
by the former name of caspase-1, IL-1b-
converting enzyme. Mature and active
IL-1b is a powerful proinflammatory
cytokine critically involved in the
induction of an inflammatory response
(Dinarello, 2009). Caspase-1 also
activates proIL-18, a cytokine involved
in the recruitment of T cells and in the
induction of IFNg. In contrast to proIL-
1b, proIL-1a, which binds to the same
receptor as IL-1b, is already active.
Limited proteolysis enhances the acti-
vity of proIL-1a; however, this occurs
independently of caspase-1 (Afonina
et al., 2011). Still, caspase-1 activity is
linked to proIL-1a as the protease can
regulate the release of the cytokine and
of several other proteins involved in
inflammation and repair. ProIL-1a, -b,
-18, and additional proteins with an
extracellular function lack a signal pep-
tide. Nevertheless, these proteins leave
the cell, but they do it independently of
the classical secretion pathway by a
poorly understood alternative mecha-
nism called unconventional protein
secretion that is regulated by caspase-1
activity (Nickel and Rabouille, 2009).
However, proIL-1a secretion can also
occur independently of caspase-1
(Gross et al., 2012; Lukens et al.,
2013) or the cytokine can be active on
the cell surface (Fettelschoss et al.,
2011). In contrast to most other
caspases, caspase-1 is considered to be
not involved in apoptosis but in a lytic
and inflammation-supporting form of
programmed cell death named pyrop-
tosis (Bergsbaken et al., 2009). The
intracellular bacterium Salmonella
typhimurium induces this type of cell
death in a NLRC4-dependent but ASC-
independent manner in macrophages,
but not in neutrophils (Miao and
Warren, 2010). Other activators of and
cell types for pyroptosis are being
discussed (Bergsbaken et al., 2009).
Pyroptosis is characterized by DNA
fragmentation that occurs without
activation of apoptotic caspases and is
only dependent on caspase-1. Most
importantly, pyroptotic cell death is
characterized by cell lysis and the
release of DAMPs (that can induce
inflammasome activation in other cells)
and of additional proinflammatory
molecules termed alarmins, such as
HMGB1 (high-mobility group box 1)
and members of the S100 family, with
the latter activating Toll-like receptors.
The existence of these IL-1b-
independent effector mechanisms of
inflammasomes raise the possibility
that diseases with an involvement of
inflammasomes are not always pri-
marily mediated by IL-1b and can
consequently not be efficiently treated
by IL-1 blockers.
INFLAMMASOME ACTIVITY IN
KERATINOCYTES
In addition to their mechanical barrier
function, keratinocytes are immunologi-
cally active, responding to injuries and
danger signals by secreting proinflam-
matory cytokines. Although inflamma-
somes have been mainly characterized
in professional immune cells such
as macrophages and dendritic cells,
at least the NLRP1, NLRP3, and AIM2
inflammasomes are also expressed by
keratinocytes. UVB irradiation activates
the NLRP1 and NLRP3 inflammasomes
with subsequent IL-1b secretion in
human primary keratinocytes in a cyto-
plasmic Ca2þ concentration–dependent
manner (Feldmeyer et al., 2007). In
addition, the NLRP3 inflammasome in
keratinocytes is able to sense different
contact sensitizers and is involved in the
sensitization phase of contact hyper-
sensitivity (CHS) (Watanabe et al.,
2007). In psoriasis, cytosolic DNA,
which is detected in keratinocytes of
lesional skin, is suspected to act as a
DAMP activating the AIM2 inflamma-
some (Dombrowski et al., 2011). The
AIM2 inflammasome is also activated by
human papillomavirus 16 and honey
bee venom (Dombrowski et al., 2012;
Reinholz et al., 2013). In spite of the
above evidence that keratinocytes can
effectively mount innate immune
responses to DAMPs, their contribution
in the cutaneous manifestations of
autoinflammatory diseases has not
been investigated to date.
AUTOINFLAMMATORY DISEASES
Inflammasomes have not only a crucial
and beneficial role in many pathogen-
or danger-induced acute inflammations,
but can also cause a relatively new
family of so-called autoinflammatory
diseases (Dinarello, 2009) (Figure 1).
These diseases are characterized by see-
mingly unprovoked inflammation in the
absence of high-titer antibodies and
antigen-specific T cell responses
(Masters et al., 2009). Interestingly,
several of them are characterized by
cutaneous neutrophilic inflammation
and skin signs are important markers of
disease activity. Most importantly,
autoinflammatory diseases respond
well to the treatment with different
IL-1 blockers such as Anakinra, the
recombinant version of the naturally
occurring IL-1 receptor antagonist.
Consequently, autoinflammatory disea-
ses have also been defined by their
responsiveness to IL-1 blockade
(Dinarello, 2009) (Figure 2 and Table 1).
Cryopyrin-associated periodic syndromes
Cryopyrin-associated periodic syndromes
(CAPS) are prototypic autoinflammatory
diseases caused by autosomal dominant
mutations in the NLRP3 gene (Hoffman
et al., 2001; Agostini et al., 2004). CAPS
include familial cold autoinflammatory
syndrome, Muckle–Wells syndrome,
and chronic infantile neurological cuta-
neous and articular syndrome, also
known as neonatal-onset multisystem
inflammatory disease.
CAPS are characterized by periodic
fever syndromes associated with urti-
caria-like skin lesions. In CAPS patients,
the mutations identified in NLRP3 mark-
edly lower its activation threshold, thus
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leading to seemingly unprovoked acti-
vation of caspase-1 and subsequent
abnormal IL-1b secretion (Agostini
et al., 2004). Mice expressing human
NLRP3 mutants develop clinical manife-
stations of CAPS and exhibit features
recapitulating the human disease with
notably overt neutrophilic skin infiltra-
tion and a T helper type 17 (Th17)
cytokine profile in skin lesions (Brydges
et al., 2009). The T cell response in the
skin of CAPS patients appears to be
limited to IL-1b-dependent Th17, and
does not involve Th1 or Th2, as
observed in CHS. Therefore, although
IL-1b has a key role in both CHS and
CAPS pathogenesis, additional conditions
such as the presence of exogenous
antigen(s), as is the case for CHS, may
account for different manifestations
involving subset-dependent CD4þ T
cell–driven pathomechanisms.
In accordance with the pathogenetic
role of IL-1b in CAPS, IL-1 inhibitors
are extremely successful for their treat-
ment (Hoffman et al., 2004, 2008;
Lachmann et al., 2009; Kone-Paut
et al., 2011).
Studies in mice expressing Nlrp3
mutants mimicking the mutations found
in human CAPS (Brydges et al., 2009;
Meng et al., 2009) suggest that skin-
resident immune cells may be
responsible for the abnormal IL-1b
production. Indeed, the two initial
reports describing the development of
neutrophil-rich dermatitis resembling
human CAPS showed that the priming
of macrophages from Nlrp3-mutant
mice with Toll-like receptor agonists
alone (signal 1) induced a robust IL-1b
production and that Nlrp3 mutations in
bone marrow–derived cells are suffi-
cient to induce a CAPS phenotype in
mice (Meng et al., 2009). Consistently,
with these observations in mice, it has
been observed that most of the IL-1b-
positive cells in the skin lesions of CAPS
patients are mast cells that can produce
IL-1b in an Nlrp3-dependent manner
(Nakamura et al., 2009). More
recently, it has been shown that mast
cells have a critical role in triggering the
neonatal form of the disease in mice
(Nakamura et al., 2012). To date, there
are no functional data showing that
keratinocytes are directly involved in
IL-1b overproduction in autoinflam-
matory disorders. Because of the
propensity of keratinocytes to strongly
react to DAMPs, a substantial contri-
bution of keratinocytes to the recruit-
ment of neutrophils to the skin via IL-1b
cannot be excluded.
Schnitzler’s syndrome
Schnitzler’s syndrome is characterized
by chronic urticaria and an IgM gam-
mopathy accompanied by recurrent
fever, arthritis or arthralgia, and bone
pain among others (Asahina et al.,
2010). The exact etiology and patho-
genesis of Schnitzler’s syndrome remain
to be clarified, but IL-1b appears to
crucially contribute to the systemic
inflammation occurring in these
patients as enhanced IL-1 secretion by
peripheral blood mononuclear cells
from patients can be normalized by
Anakinra (Launay et al., 2013), and
Anakinra (Volz et al., 2012), Rilonacept
(Krause et al., 2012) and Canakinumab
have emerged as effective therapeutic
options (de Koning et al., 2011).
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Figure 1. Deregulation of IL-1b production and signaling is associated with autoinflammatory disorders.
Mutations in the NLRP3 gene lead to a constitutive inflammasome activation in CAPS patients.
Hyperphosphorylated variants of PSTPIP1 such as the ones causing PAPA syndrome are known to have a
higher affinity for pyrin than wild-type PSTPIP1. The binding of PSTPIP1 variants to the regulatory domain
of pyrin relieves its inhibitory activity, resulting in pyrin activation and subsequent ASC oligomerization
and caspase-1 activation in PAPA syndrome, thereby relating PAPA syndrome and familial Mediterranean
fever. In DIRA, the absence of IL-1RA production leads to an uncontrolled IL-1 overactivity. ASC,
apoptosis-associated speck-like protein containing a CARD; CARD, caspase recruitment domain; CAPS,
cryopyrin-associated periodic syndrome; DIRA, deficiency of IL-1 receptor antagonist; IL-1RA, IL-1
receptor antagonist; LRR, leucine-rich repeat; PAPA, pyogenic arthritis–pyoderma gangrenosum–acne;
PSTPIP1, proline–serine–threonine phosphatase-interactive protein 1.
IL-1β IL-1βIL-1β
IL-1RI
Kineret
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Figure 2. Current IL-1b-blocking strategies. Clinically available drugs consist of soluble recombinant
IL-1RA (Anakinra), blocking anti-IL-1b antibodies (Canakinumab and Gevokizumab), and a dimeric fusion
protein consisting of the ligand-binding domains of IL-1R1 and IL-1 receptor accessory protein (IL-1RAcP)
linked to the human Fc fragment of IgG1 (Rilonacept). IL-1RA, IL-1 receptor antagonist.
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Deficiency of IL-1 receptor antagonist
(DIRA)
DIRA is a severe autosomal recessive
inherited disease caused by the homo-
zygous loss-of-function mutations in
IL1RN leading to the absence of IL-1
receptor antagonist production and sub-
sequent IL-1 overactivity (Aksentijevich
et al., 2009; Reddy et al., 2009).
Clinically, DIRA manifests itself with
perinatal-onset pustular dermatitis, joint
swelling, painful osteolytic lesions, and
periosteitis. Treatment with Anakinra,
a soluble recombinant IL-1 receptor
antagonist, induces rapid and complete
clinical improvement (Aksentijevich
et al., 2009; Schnellbacher et al., 2012).
PAPA syndrome
PAPA (pyogenic arthritis–pyoderma
gangrenosum–acne) syndrome is an
inherited disorder caused by an auto-
somal dominant mutation in PSTPIP1
(proline–serine–threonine phosphatase-
interactive protein 1) (Nesterovitch
et al., 2011). A deregulation of
caspase-1 activation and an increased
production of IL-1b as well as tumor
necrosis factor in peripheral blood
mononuclear cells have been reported
(Shoham et al., 2003; Cortis et al.,
2004). PSTPIP1 mutants have been
shown to induce proIL-1b processing
by caspase-1 (Yu et al., 2007; Wang
et al., 2013) and Anakinra has been
shown to be effective in the control of
inflammatory manifestations in certain
patients (Dierselhuis et al., 2005;
Brenner et al., 2009).
SAPHO syndrome
SAPHO (synovitis, acne, pustulosis,
hyperostosis, and osteitis) syndrome is
characterized by the association of cuta-
neous manifestations—in particular,
pustular psoriasis, palmoplantar pustu-
losis, hidradenitis suppurativa, and
severe acne—with inflammatory osteo-
arthropathy. Anakinra has proven to be
efficient in the treatment of SAPHO
(Wendling et al., 2012), suggesting that
IL-1 may have an important but not
unique role in treatment, as anti-tumor
necrosis factor agents have also been
reported to induce a positive response in
SAPHO patients (Wagner et al., 2002).
CONCLUSION
The discovery of the inflammasomes a
decade ago and the new understanding
of regulation mechanisms of IL-1b have
shed light on the critical role of this
cytokine in the etiopathogenesis of the
spectrum of clinical disorders now
known as autoinflammatory diseases,
which are considered to be distinct from
autoimmune and allergic diseases. Inter-
estingly, a common denominator in
these diseases is the neutrophil-rich
nature of the inflammation with a skin
involvement. However, the nature of the
cells abnormally producing IL-1b in the
skin of patients with autoinflammatory
disorders remains to be determined.
Indeed, to our knowledge, functional
studies in these patients have been
performed using peripheral blood cells.
Therefore, the respective contribution of
skin cell types such as keratinocytes or
macrophages to the cutaneous manifes-
tations of autoinflammation remains to
be investigated. Murine models based
on conditional, cell type–specific knock-
in of inflammasome mutants would be
of great interest to address this issue. In
addition, we are far from understanding
individual, patient-specific factors or
from obtaining the answer to the ques-
tion of why the skin tolerates certain
bacteria and substances, whereas others
cause an inflammation. Of further inter-
est to clinicians in search for the etiol-
ogy of disease is the fact that acne,
Table 1. Autoinflammatory disorders with skin involvement
Disease Defective molecule Inheritance IL-1-targeting treatment Target molecule
CAPS
FCAS NLRP3 Autosomal dominant Anakinra
Rilonacept
Canakinumab
IL-1R1
IL-1b
IL-1b
MWS NLRP3 Autosomal dominant Anakinra
Rilonacept
Canakinumab
IL-1R1
IL-1b
IL-1b
CINCA NLRP3 Autosomal dominant Anakinra
Canakinumab
IL-1R1
IL-1b
Other inflammatory disorders
DIRA IL-1RA Autosomal recessive Anakinra IL-1R1
PAPA syndrome PSTPIP1 Autosomal dominant Anakinra IL-1R1
Schnitzler’s syndrome Unknown Unknown Anakinra
Rilonacept
Canakinumab
IL-1R1
IL-1b
IL-1b
SAPHO Unknown Unknown Anakinra IL-1R1
Abbreviations: CAPS, cryopyrin-associated periodic syndrome; CINCA, chronic infantile neurological cutaneous and articular syndrome; DIRA, deficiency of
IL-1 receptor antagonist; FCAS, familial cold autoinflammatory syndrome; IL-1RA, IL-1 receptor antagonist; MWS, Muckle–Wells syndrome; NLRP3, NOD,
leucine-rich repeat and pyrin domain containing protein 3; PAPA syndrome, pyogenic arthritis–pyoderma gangrenosum–acne syndrome; PSTPIP1, proline–
serine–threonine phosphatase-interactive protein 1; SAPHO, synovitis, acne, pustulosis, hyperostosis, and osteitis.
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pyoderma gangrenosum, psoriasiform
pustulosis, and urticaria-like lesions are
also clinical presentations observed in
autoinflammatory diseases resulting
from a deregulation of IL-1. This raises
the question as to a possible role of the
inflammasomes and/or IL-1 in more
common neutrophilic dermatoses such
as acne, pyoderma gangrenosum, hidra-
denitis suppurutiva, pustular psoriasis,
Sweet’s syndrome, and acute general-
ized exanthematic pustulosis. Although
the etiology and physiopathology of
some autoinflammatory disorders remain
enigmatic, targeted therapies against
IL-1 have proven to be efficient and
induce sustained remission in a substan-
tial number of patients. Further investi-
gation of the molecular nature of the
above diseases may prove that IL-1,
downstream cytokines induced by IL-1
signaling, T cell subtypes such as Th17
that are partially dependent on IL-1b for
their phenotypic maturation, or other
inflammasome effector mechanisms
have a role in their pathogenesis. The
increasing number of agents for target-
ing these pathways that are currently
available or under development in clin-
ical trials promises a better future for
clinicians taking care of patients with
such diseases.
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